Drug intelligence / Profile preview

CC-885

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

CC-885 is a cereblon (CRBN) modulator and molecular glue degrader with potent anti-tumor activity. Originally developed by Celgene Corporation, it promotes CRL4^CRBN^ E3 ubiquitin ligase-dependent degradation of multiple target proteins including GSPT1, BNIP3L, PLK1, and GOLM1. The compound contains a glutarimide ring that directly interacts with CRBN. CC-885 has demonstrated synergistic effects with volasertib in NSCLC and shows promise in combination therapies for AML and HCC. Primary indications under investigation include hepatocellular carcinoma, non-small-cell lung cancer, and acute myeloid leukemia.

Targets

CRBN (Cereblon)GOLM1 (Golgi membrane protein 1)GSPT1 (G1 to S phase transition 1)

Beyond the preview

Go deeper on CC-885.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-885.

Explore the full profile